$BRFH
BARFRESH FOOD GROUP INC. Stock $brfh

$brfh Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000149315224042368 Filed on October 24, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2023 Q4
Revenue		$3.637M	$1.922M
YoY Change		39.72%	34.31%
Cost Of Revenue		$2.377M	$1.280M
YoY Change		40.65%	39.89%
Gross Profit		$1.260M	$642.0K
YoY Change		38.01%	24.42%
Gross Profit Margin		34.64%	33.4%
Selling, General & Admin		$1.695M	$1.226M
YoY Change		32.94%	-18.38%
% of Gross Profit		134.52%	190.97%
Research & Development		$52.00K	$27.00K
YoY Change		62.5%	-22.86%
% of Gross Profit		4.13%	4.21%
Depreciation & Amortization		$55.00K	$73.00K
YoY Change		-46.08%	-40.16%
% of Gross Profit		4.37%	11.37%
Operating Expenses		$1.760M	$1.343M
YoY Change		26.71%	-18.61%
Operating Profit		-$500.0K	-$701.0K
YoY Change		5.04%	-38.18%
Interest Expense		-$13.00K
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income		-$513.0K	-$701.0K
YoY Change		6.88%	-62.71%
Income Tax
% Of Pretax Income
Net Earnings		-$513.0K	-$701.0K
YoY Change		7.77%	-62.71%
Net Earnings / Revenue		-14.11%	-36.47%
Basic Earnings Per Share		-$0.03
Diluted Earnings Per Share		-$0.03	-$0.05
COMMON SHARES
Basic Shares Outstanding	14.75M shares	14.75M shares	13.92M shares
Diluted Shares Outstanding		14.74M shares

Balance Sheet

Concept	2024 Q3	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$401.0K	$1.891M
YoY Change	-60.3%	-32.66%
Cash & Equivalents	$401.0K	$1.891M
Short-Term Investments
Other Short-Term Assets	$226.0K	$67.00K
YoY Change	32.94%	-76.9%
Inventory	$770.0K	$1.214M
Prepaid Expenses
Receivables	$1.663M	$821.0K
Other Receivables	$30.00K	$160.0K
Total Short-Term Assets	$3.090M	$4.153M
YoY Change	-3.47%	-5.03%
LONG-TERM ASSETS
Property, Plant & Equipment	$390.0K	$409.0K
YoY Change	-19.92%	5.14%
Goodwill
YoY Change
Intangibles	$194.0K	$241.0K
YoY Change	-24.81%	-21.24%
Long-Term Investments
YoY Change
Other Assets	$98.00K	$7.000K
YoY Change	880.0%	0.0%
Total Long-Term Assets	$682.0K	$657.0K
YoY Change	-9.31%	-8.75%
TOTAL ASSETS
Total Short-Term Assets	$3.090M	$4.153M
Total Long-Term Assets	$682.0K	$657.0K
Total Assets	$3.772M	$4.810M
YoY Change	-4.58%	-5.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.220M	$1.670M
YoY Change	-27.9%	-17.86%
Accrued Expenses	$270.0K	$85.00K
YoY Change	17.9%	-70.28%
Deferred Revenue
YoY Change
Short-Term Debt	$86.00K	$0.00
YoY Change
Long-Term Debt Due	$95.00K
YoY Change
Total Short-Term Liabilities	$2.218M	$2.307M
YoY Change	-16.62%	-10.3%
LONG-TERM LIABILITIES
Long-Term Debt	$151.0K	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$151.0K	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.218M	$2.307M
Total Long-Term Liabilities	$151.0K	$0.00
Total Liabilities	$2.369M	$2.307M
YoY Change	-10.94%	-10.3%
SHAREHOLDERS EQUITY
Retained Earnings	-$62.77M	-$60.80M
YoY Change	4.45%	4.13%
Common Stock	$0.00	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.403M	$2.503M
YoY Change
Total Liabilities & Shareholders Equity	$3.772M	$4.810M
YoY Change	-4.58%	-5.56%

Cashflow Statement

Concept	2024 Q3	2023 Q4
OPERATING ACTIVITIES
Net Income	-$513.0K	-$701.0K
YoY Change	7.77%	-62.71%
Depreciation, Depletion And Amortization	$55.00K	$73.00K
YoY Change	-46.08%	-40.16%
Cash From Operating Activities	$5.000K	-$948.0K
YoY Change	-91.67%	3168.97%
INVESTING ACTIVITIES
Capital Expenditures	$57.00K	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$57.00K	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	70.00K	1.830M
YoY Change
NET CHANGE
Cash From Operating Activities	5.000K	-948.0K
Cash From Investing Activities	-57.00K	0.000
Cash From Financing Activities	70.00K	1.830M
Net Change In Cash	18.00K	882.0K
YoY Change	-70.0%	-3141.38%
FREE CASH FLOW
Cash From Operating Activities	$5.000K	-$948.0K
Capital Expenditures	$57.00K	$0.00
Free Cash Flow	-$52.00K	-$948.0K
YoY Change	-186.67%	3168.97%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue		usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q3	us-gaap	Common Stock Value CommonStockValue		usd
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	697000	usd
CY2024Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	30000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	770000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	3090000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	390000	usd
CY2024Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	194000	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	98000	usd
CY2024Q3	us-gaap	Assets Assets	3772000	usd
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001487197
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-41228
	dei	Entity Registrant Name EntityRegistrantName	BARFRESH FOOD GROUP INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Address Address Line1 EntityAddressAddressLine1	3600 Wilshire Blvd.
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1720
	dei	Entity Address City Or Town EntityAddressCityOrTown	Los Angeles
	dei	City Area Code CityAreaCode	310
	dei	Local Phone Number LocalPhoneNumber	598-7113
	dei	Entity Information Former Legal Or Registered Name EntityInformationFormerLegalOrRegisteredName	Not Applicable
	dei	Security12b Title Security12bTitle	Common stock, $0.000001 par value
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	14746172	shares
CY2024Q3	us-gaap	Cash Cash	401000	usd
CY2023Q4	us-gaap	Cash Cash	1891000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	821000	usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	160000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	1214000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	67000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	4153000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	409000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	241000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7000	usd
CY2023Q4	us-gaap	Assets Assets	4810000	usd
	dei	Amendment Flag AmendmentFlag	false
CY2023Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent		usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent		usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent		usd
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
	BRFH	Amortization Of Debt Discounts AmortizationOfDebtDiscounts		usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit		usd
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit		usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
	BRFH	Payments Of Financing Agreement PaymentsOfFinancingAgreement		usd
	BRFH	Amounts Included In Measurement Of Lease Liabilities AmountsIncludedInMeasurementOfLeaseLiabilities		usd
	us-gaap	Notes Issued1 NotesIssued1		usd
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1		usd
	BRFH	Financed Acquisition Of Longterm Assets FinancedAcquisitionOfLongtermAssets		usd
	BRFH	Value Of Shares Relinquished In Modification Of Stockbased Compensations Awards ValueOfSharesRelinquishedInModificationOfStockbasedCompensationsAwards		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Trading Symbol TradingSymbol	BRFH
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1220000	usd
CY2024Q3	us-gaap	Accounts Payable Underwriters Promoters And Employees Other Than Salaries And Wages Current AccountsPayableUnderwritersPromotersAndEmployeesOtherThanSalariesAndWagesCurrent	499000	usd
CY2023Q4	us-gaap	Accounts Payable Underwriters Promoters And Employees Other Than Salaries And Wages Current AccountsPayableUnderwritersPromotersAndEmployeesOtherThanSalariesAndWagesCurrent	499000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	270000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	85000	usd
CY2024Q3	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	48000	usd
CY2023Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	53000	usd
CY2024Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	95000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	2218000	usd
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-1994406
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	90010
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1663000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	226000	usd
CY2024Q3	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	86000	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1220000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1670000	usd
CY2024Q3	us-gaap	Accounts Payable Underwriters Promoters And Employees Other Than Salaries And Wages Current AccountsPayableUnderwritersPromotersAndEmployeesOtherThanSalariesAndWagesCurrent	499000	usd
CY2023Q4	us-gaap	Accounts Payable Underwriters Promoters And Employees Other Than Salaries And Wages Current AccountsPayableUnderwritersPromotersAndEmployeesOtherThanSalariesAndWagesCurrent	499000	usd
CY2024Q3	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	48000	usd
CY2023Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	53000	usd
CY2024Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	95000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	2218000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2307000	usd
CY2024Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	151000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-444000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-300000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	95000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	27000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	195000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	180000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-137000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1544000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-61000	usd
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	930000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	65000	usd
	BRFH	Payments Of Financing Agreement PaymentsOfFinancingAgreement	13000	usd
	BRFH	Repurchases From Stock Compensation Program RepurchasesFromStockCompensationProgram	20000	usd
	BRFH	Repurchases From Stock Compensation Program RepurchasesFromStockCompensationProgram	18000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	115000	usd
CY2024Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	151000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	2369000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	2307000	usd
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.000001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.000001
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	400000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	400000	shares
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.000001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.000001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	23000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	23000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14746172	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14746172	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14420105	shares
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	63299000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-62769000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-60796000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	2503000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3772000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2603000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7929000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6205000	usd
CY2024Q3	us-gaap	Cost Of Revenue CostOfRevenue	2377000	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	1690000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	4991000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	3963000	usd
CY2024Q3	us-gaap	Gross Profit GrossProfit	1260000	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	913000	usd
	us-gaap	Gross Profit GrossProfit	2938000	usd
	us-gaap	Gross Profit GrossProfit	2242000	usd
CY2024Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	990000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2267000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1990000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	577000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2062000	usd
CY2024Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	65000	usd
CY2023Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	114000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	197000	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	1760000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	1388000	usd
	us-gaap	Operating Expenses OperatingExpenses	4362000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-475000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1949000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2120000	usd
CY2024Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	13000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	24000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-513000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-476000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1973000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	2369000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	2307000	usd
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.000001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.000001
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	400000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	400000	shares
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.000001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.000001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	23000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14746172	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14746172	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14420105	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14420105	shares
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	64172000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	63299000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-62769000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-60796000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	1403000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	2503000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3772000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4810000	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3637000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2603000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7929000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6205000	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	1690000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	4991000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	3963000	usd
CY2024Q3	us-gaap	Gross Profit GrossProfit	1260000	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	913000	usd
	us-gaap	Gross Profit GrossProfit	2938000	usd
	us-gaap	Gross Profit GrossProfit	2242000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2267000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1990000	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	705000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	577000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2423000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2062000	usd
CY2024Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	65000	usd
CY2023Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	114000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	197000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	310000	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	1760000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	1388000	usd
	us-gaap	Operating Expenses OperatingExpenses	4887000	usd
	us-gaap	Operating Expenses OperatingExpenses	4362000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-500000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-475000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1949000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2120000	usd
CY2024Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	13000	usd
CY2023Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	1000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	24000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	3000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-513000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-476000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1973000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2123000	usd
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14744000	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14744000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13036000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13036000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14655000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13005000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13005000	shares
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
	us-gaap	Net Income Loss NetIncomeLoss	-1973000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2123000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	757000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	514000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	217000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	325000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	842000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1033000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-130000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-300000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	27000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-379000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	180000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-61000	usd
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	930000	usd
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	847000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	65000	usd
	BRFH	Payments Of Financing Agreement PaymentsOfFinancingAgreement	13000	usd
	BRFH	Repurchases From Stock Compensation Program RepurchasesFromStockCompensationProgram	20000	usd
	BRFH	Repurchases From Stock Compensation Program RepurchasesFromStockCompensationProgram	18000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	115000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-18000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1891000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3019000	usd
	BRFH	Amounts Included In Measurement Of Lease Liabilities AmountsIncludedInMeasurementOfLeaseLiabilities	20000	usd
	us-gaap	Notes Issued1 NotesIssued1	71000	usd
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	136000	usd
	BRFH	Financed Acquisition Of Longterm Assets FinancedAcquisitionOfLongtermAssets	245000	usd
	BRFH	Value Of Shares Relinquished In Modification Of Stockbased Compensations Awards ValueOfSharesRelinquishedInModificationOfStockbasedCompensationsAwards	24000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2123000	usd
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14744000	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14744000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13036000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13036000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14655000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14655000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13005000	shares
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
	us-gaap	Net Income Loss NetIncomeLoss	-1973000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2123000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	757000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	514000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	217000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	325000	usd
	BRFH	Amortization Of Debt Discounts AmortizationOfDebtDiscounts	17000	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	11000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	842000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1033000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-130000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	15000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-444000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-300000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	95000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	27000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-379000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-137000	usd
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	930000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	65000	usd
	BRFH	Payments Of Financing Agreement PaymentsOfFinancingAgreement	13000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	115000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-18000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2008000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	401000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1011000	usd
	BRFH	Amounts Included In Measurement Of Lease Liabilities AmountsIncludedInMeasurementOfLeaseLiabilities	20000	usd
	BRFH	Financed Acquisition Of Longterm Assets FinancedAcquisitionOfLongtermAssets	245000	usd
	BRFH	Value Of Shares Relinquished In Modification Of Stockbased Compensations Awards ValueOfSharesRelinquishedInModificationOfStockbasedCompensationsAwards	24000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-130000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	15000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-444000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	27000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-379000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-137000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1544000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1990000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	61000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-61000	usd
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	930000	usd
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	847000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	65000	usd
	BRFH	Payments Of Financing Agreement PaymentsOfFinancingAgreement	13000	usd
	BRFH	Repurchases From Stock Compensation Program RepurchasesFromStockCompensationProgram	20000	usd
	BRFH	Repurchases From Stock Compensation Program RepurchasesFromStockCompensationProgram	18000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-18000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1490000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3019000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	401000	usd
	BRFH	Amounts Included In Measurement Of Lease Liabilities AmountsIncludedInMeasurementOfLeaseLiabilities	20000	usd
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	136000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_840_eus-gaap--UseOfEstimates_zOGkCAY1dWP6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_zGBGCrTIB40i">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities in the balance sheets and revenues and expenses during the years reported. Actual results may differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_zAqPIT6189vb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_zawUXdj4JaC3">Vendor Concentrations</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is exposed to supply risk as a result of concentration in its vendor base resulting from the use of a limited number of contract manufacturers. Purchases from the Company’s significant contract manufacturers as a percentage of all finished goods purchased were as follows:</span></p> <p id="xdx_894_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_zFbp1OBEhQ03" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B1_zTMGX2FnpeKk" style="display: none">Schedule of Contract Manufacturers Percentage of Finished Goods</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 95%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20240701__20240930_zgSNOeZcgDba" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20230701__20230930_zI4jxwYf1Aob" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20240101__20240930_zjFctuWJ1erk" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20230101__20230930_zzfYHOV7FZw3" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the three months ended September 30,</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the nine months ended September 30,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--ManufacturerAMember_zJoOPP31baM5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">Manufacturer A</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">63</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">55</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">58</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">47</td><td style="width: 1%; text-align: left">%</td></tr> <tr id="xdx_405_eus-gaap--ConcentrationRiskPercentage1_pid_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--ManufacturerBMember_zWtViTGLPwEb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Manufacturer B</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">37</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">37</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">44</td><td style="text-align: left">%</td></tr> <tr id="xdx_40F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--ManufacturerCMember_zN8qfPYgN4Jb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Manufacturer C</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--ConcentrationRiskPercentage1_pid_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zLHXpSftLe1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Concentration risk percentage</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p> <p id="xdx_8A9_zAjqX4YEJ1Ci" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p>
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-18000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1490000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2008000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1891000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1011000	usd
	BRFH	Amounts Included In Measurement Of Lease Liabilities AmountsIncludedInMeasurementOfLeaseLiabilities	20000	usd
	BRFH	Financed Acquisition Of Longterm Assets FinancedAcquisitionOfLongtermAssets	245000	usd
	BRFH	Value Of Shares Relinquished In Modification Of Stockbased Compensations Awards ValueOfSharesRelinquishedInModificationOfStockbasedCompensationsAwards	24000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_840_eus-gaap--UseOfEstimates_zOGkCAY1dWP6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_zGBGCrTIB40i">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities in the balance sheets and revenues and expenses during the years reported. Actual results may differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_zAqPIT6189vb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_zawUXdj4JaC3">Vendor Concentrations</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is exposed to supply risk as a result of concentration in its vendor base resulting from the use of a limited number of contract manufacturers. Purchases from the Company’s significant contract manufacturers as a percentage of all finished goods purchased were as follows:</span></p> <p id="xdx_894_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_zFbp1OBEhQ03" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B1_zTMGX2FnpeKk" style="display: none">Schedule of Contract Manufacturers Percentage of Finished Goods</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 95%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20240701__20240930_zgSNOeZcgDba" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20230701__20230930_zI4jxwYf1Aob" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20240101__20240930_zjFctuWJ1erk" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20230101__20230930_zzfYHOV7FZw3" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the three months ended September 30,</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the nine months ended September 30,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--ManufacturerAMember_zJoOPP31baM5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">Manufacturer A</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">63</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">55</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">58</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">47</td><td style="width: 1%; text-align: left">%</td></tr> <tr id="xdx_405_eus-gaap--ConcentrationRiskPercentage1_pid_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--ManufacturerBMember_zWtViTGLPwEb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Manufacturer B</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">37</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">37</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">44</td><td style="text-align: left">%</td></tr> <tr id="xdx_40F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--ManufacturerCMember_zN8qfPYgN4Jb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Manufacturer C</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--ConcentrationRiskPercentage1_pid_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zLHXpSftLe1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Concentration risk percentage</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p> <p id="xdx_8A9_zAjqX4YEJ1Ci" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p>
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_840_eus-gaap--UseOfEstimates_zOGkCAY1dWP6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_zGBGCrTIB40i">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities in the balance sheets and revenues and expenses during the years reported. Actual results may differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_zAqPIT6189vb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_zawUXdj4JaC3">Vendor Concentrations</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is exposed to supply risk as a result of concentration in its vendor base resulting from the use of a limited number of contract manufacturers. Purchases from the Company’s significant contract manufacturers as a percentage of all finished goods purchased were as follows:</span></p> <p id="xdx_894_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_zFbp1OBEhQ03" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B1_zTMGX2FnpeKk" style="display: none">Schedule of Contract Manufacturers Percentage of Finished Goods</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 95%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20240701__20240930_zgSNOeZcgDba" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20230701__20230930_zI4jxwYf1Aob" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20240101__20240930_zjFctuWJ1erk" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20230101__20230930_zzfYHOV7FZw3" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the three months ended September 30,</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the nine months ended September 30,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--ManufacturerAMember_zJoOPP31baM5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">Manufacturer A</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">63</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">55</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">58</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">47</td><td style="width: 1%; text-align: left">%</td></tr> <tr id="xdx_405_eus-gaap--ConcentrationRiskPercentage1_pid_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--ManufacturerBMember_zWtViTGLPwEb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Manufacturer B</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">37</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">37</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">44</td><td style="text-align: left">%</td></tr> <tr id="xdx_40F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--ManufacturerCMember_zN8qfPYgN4Jb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Manufacturer C</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--ConcentrationRiskPercentage1_pid_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zLHXpSftLe1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Concentration risk percentage</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p> <p id="xdx_8A9_zAjqX4YEJ1Ci" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_zAqPIT6189vb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_zawUXdj4JaC3">Vendor Concentrations</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is exposed to supply risk as a result of concentration in its vendor base resulting from the use of a limited number of contract manufacturers. Purchases from the Company’s significant contract manufacturers as a percentage of all finished goods purchased were as follows:</span></p> <p id="xdx_894_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_zFbp1OBEhQ03" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B1_zTMGX2FnpeKk" style="display: none">Schedule of Contract Manufacturers Percentage of Finished Goods</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 95%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20240701__20240930_zgSNOeZcgDba" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20230701__20230930_zI4jxwYf1Aob" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20240101__20240930_zjFctuWJ1erk" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20230101__20230930_zzfYHOV7FZw3" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the three months ended September 30,</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the nine months ended September 30,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--ManufacturerAMember_zJoOPP31baM5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">Manufacturer A</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">63</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">55</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">58</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">47</td><td style="width: 1%; text-align: left">%</td></tr> <tr id="xdx_405_eus-gaap--ConcentrationRiskPercentage1_pid_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--ManufacturerBMember_zWtViTGLPwEb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Manufacturer B</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">37</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">37</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">44</td><td style="text-align: left">%</td></tr> <tr id="xdx_40F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--ManufacturerCMember_zN8qfPYgN4Jb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Manufacturer C</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--ConcentrationRiskPercentage1_pid_dp_hus-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zLHXpSftLe1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Concentration risk percentage</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p> <p id="xdx_8A9_zAjqX4YEJ1Ci" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p>
CY2024Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2024Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
CY2024Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2023Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2024Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2024Q3	BRFH	Shipping And Storage Costs ShippingAndStorageCosts	480000	usd
CY2023Q3	BRFH	Shipping And Storage Costs ShippingAndStorageCosts	370000	usd
	BRFH	Shipping And Storage Costs ShippingAndStorageCosts	1061000	usd
	BRFH	Shipping And Storage Costs ShippingAndStorageCosts	932000	usd
CY2024Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
CY2024Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2023Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2023Q3	BRFH	Shipping And Storage Costs ShippingAndStorageCosts	370000	usd
	BRFH	Shipping And Storage Costs ShippingAndStorageCosts	1061000	usd
	BRFH	Shipping And Storage Costs ShippingAndStorageCosts	932000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	32000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	99000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	88000	usd
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_847_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zLxSJhkz3jRc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zlHDEBXVm3ci">Reclassifications</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain reclassifications have been made to the 2023 financial statements to conform to the 2024 presentation, namely stock-based compensation paid to the Company’s directors has been reclassified from stock and options issued for services and shares repurchased for employee tax withholding under the Company’s stock compensation program have been reclassified to financing activities in the consolidated statement of cash flows, with corresponding changes reflected in the statement of stockholders’ equity for the nine months ended September 30, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q3	BRFH	Shipping And Storage Costs ShippingAndStorageCosts	480000	usd
CY2023Q3	BRFH	Shipping And Storage Costs ShippingAndStorageCosts	370000	usd
	BRFH	Shipping And Storage Costs ShippingAndStorageCosts	1061000	usd
	BRFH	Shipping And Storage Costs ShippingAndStorageCosts	932000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	32000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	99000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	88000	usd
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_847_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zLxSJhkz3jRc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zlHDEBXVm3ci">Reclassifications</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain reclassifications have been made to the 2023 financial statements to conform to the 2024 presentation, namely stock-based compensation paid to the Company’s directors has been reclassified from stock and options issued for services and shares repurchased for employee tax withholding under the Company’s stock compensation program have been reclassified to financing activities in the consolidated statement of cash flows, with corresponding changes reflected in the statement of stockholders’ equity for the nine months ended September 30, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q3	BRFH	Shipping And Storage Costs ShippingAndStorageCosts	480000	usd
CY2023Q3	BRFH	Shipping And Storage Costs ShippingAndStorageCosts	370000	usd
	BRFH	Shipping And Storage Costs ShippingAndStorageCosts	1061000	usd
	BRFH	Shipping And Storage Costs ShippingAndStorageCosts	932000	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	52000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	32000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	99000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	88000	usd
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_847_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zLxSJhkz3jRc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zlHDEBXVm3ci">Reclassifications</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain reclassifications have been made to the 2023 financial statements to conform to the 2024 presentation, namely stock-based compensation paid to the Company’s directors has been reclassified from stock and options issued for services and shares repurchased for employee tax withholding under the Company’s stock compensation program have been reclassified to financing activities in the consolidated statement of cash flows, with corresponding changes reflected in the statement of stockholders’ equity for the nine months ended September 30, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	52000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	32000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	88000	usd
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_847_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zLxSJhkz3jRc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zlHDEBXVm3ci">Reclassifications</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain reclassifications have been made to the 2023 financial statements to conform to the 2024 presentation, namely stock-based compensation paid to the Company’s directors has been reclassified from stock and options issued for services and shares repurchased for employee tax withholding under the Company’s stock compensation program have been reclassified to financing activities in the consolidated statement of cash flows, with corresponding changes reflected in the statement of stockholders’ equity for the nine months ended September 30, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	335000	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	28000	usd
CY2024Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	435000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1186000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	770000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3095000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2956000	usd
CY2024Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2705000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2547000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	390000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	409000	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	28000	usd
CY2024Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	435000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1186000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	1214000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3095000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2547000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	390000	usd
CY2023Q3	us-gaap	Depreciation Depreciation	102000	usd
	us-gaap	Depreciation Depreciation	168000	usd
	us-gaap	Depreciation Depreciation	277000	usd
CY2023Q3	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	4000	usd
	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	19000	usd
	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	13000	usd
	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2023-03-31
CY2024Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	335000	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	28000	usd
CY2024Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	435000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1186000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3095000	usd
CY2024Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2705000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2547000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	390000	usd
	us-gaap	Depreciation Depreciation	168000	usd
	us-gaap	Depreciation Depreciation	277000	usd
CY2024Q3	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	6000	usd
CY2023Q3	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	4000	usd
	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	19000	usd
	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	13000	usd
	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2023-03-31
	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	extended in a series of amendments through March 31, 2025
CY2024Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	20000	usd
CY2023Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	20000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	60000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	60000	usd
CY2022	us-gaap	Multiemployer Plan Increase In Employer Contribution Business Combination Percentage MultiemployerPlanIncreaseInEmployerContributionBusinessCombinationPercentage	0.52	pure
CY2021	us-gaap	Multiemployer Plan Increase In Employer Contribution Business Combination Percentage MultiemployerPlanIncreaseInEmployerContributionBusinessCombinationPercentage	0.42	pure
CY2024Q3	BRFH	Receivables Financing Facility ReceivablesFinancingFacility	1500000	usd
CY2024Q3	us-gaap	Line Of Credit Facility Description LineOfCreditFacilityDescription	Amounts outstanding bear interest at a rate prime plus 1.2% (9.20% as of September 30, 2024) and collateral fees of 0.15% and are secured by accounts receivable and inventory. The Facility terminates on September 5, 2025, and renews automatically, unless notice is given or received. As of September 30, 2024, borrowings under the Facility amounted to $86,000, net of unamortized deferred financing cost of $14,000, and $1,400,000 was available to borrow.
CY2024Q3	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	86000	usd
CY2024Q3	us-gaap	Deferred Costs DeferredCosts	14000	usd
CY2024Q3	us-gaap	Line Of Credit LineOfCredit	1400000	usd
CY2024Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	335000	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	28000	usd
CY2024Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	435000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1186000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	770000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	1214000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3095000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2547000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	390000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	409000	usd
CY2024Q3	us-gaap	Depreciation Depreciation	55000	usd
CY2023Q3	us-gaap	Depreciation Depreciation	102000	usd
	us-gaap	Depreciation Depreciation	168000	usd
CY2023Q3	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	4000	usd
	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	13000	usd
	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	extended in a series of amendments through March 31, 2025
CY2024Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	20000	usd
CY2023Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	20000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	60000	usd
CY2022	us-gaap	Multiemployer Plan Increase In Employer Contribution Business Combination Percentage MultiemployerPlanIncreaseInEmployerContributionBusinessCombinationPercentage	0.52	pure
CY2021	us-gaap	Multiemployer Plan Increase In Employer Contribution Business Combination Percentage MultiemployerPlanIncreaseInEmployerContributionBusinessCombinationPercentage	0.42	pure
CY2024Q3	BRFH	Receivables Financing Facility ReceivablesFinancingFacility	1500000	usd
CY2024Q3	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	86000	usd
CY2024Q3	us-gaap	Deferred Costs DeferredCosts	14000	usd
CY2024Q3	BRFH	Debt Instrument Interest Rate Imputed Percentage DebtInstrumentInterestRateImputedPercentage	0.15	pure
CY2024Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.19	pure
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	32000	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	129000	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	136000	usd
CY2024Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	297000	usd
CY2024Q3	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	51000	usd
CY2023Q3	us-gaap	Depreciation Depreciation	102000	usd
	us-gaap	Depreciation Depreciation	168000	usd
	us-gaap	Depreciation Depreciation	277000	usd
CY2024Q3	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	6000	usd
CY2023Q3	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	4000	usd
	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	19000	usd
	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	13000	usd
	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2023-03-31
	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	extended in a series of amendments through March 31, 2025
CY2024Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	20000	usd
CY2023Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	20000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	60000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	60000	usd
CY2022	us-gaap	Multiemployer Plan Increase In Employer Contribution Business Combination Percentage MultiemployerPlanIncreaseInEmployerContributionBusinessCombinationPercentage	0.52	pure
CY2024Q3	BRFH	Receivables Financing Facility ReceivablesFinancingFacility	1500000	usd
CY2024Q3	us-gaap	Line Of Credit Facility Description LineOfCreditFacilityDescription	Amounts outstanding bear interest at a rate prime plus 1.2% (9.20% as of September 30, 2024) and collateral fees of 0.15% and are secured by accounts receivable and inventory. The Facility terminates on September 5, 2025, and renews automatically, unless notice is given or received. As of September 30, 2024, borrowings under the Facility amounted to $86,000, net of unamortized deferred financing cost of $14,000, and $1,400,000 was available to borrow.
CY2024Q3	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	86000	usd
CY2024Q3	us-gaap	Deferred Costs DeferredCosts	14000	usd
CY2024Q3	us-gaap	Line Of Credit LineOfCredit	1400000	usd
CY2024Q3	BRFH	Debt Instrument Interest Rate Imputed Percentage DebtInstrumentInterestRateImputedPercentage	0.15	pure
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	32000	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	129000	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	136000	usd
CY2024Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	297000	usd
CY2024Q3	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	51000	usd
CY2024Q3	us-gaap	Long Term Debt LongTermDebt	246000	usd
CY2024Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	95000	usd
	us-gaap	Debt Instrument Description DebtInstrumentDescription	The debt was available to be drawn in 25% increments, maturing on the anniversary of the draw, bearing interest at 10% per annum for the term, regardless of earlier payment or conversion, and was mandatorily convertible as to principal and interest into shares of the Company’s common stock at any time prior to maturity at the greater of $1.20 or 85% of the volume-weighted average price of the common stock for the ten trading days immediately preceding the written notice of the conversion (the “Conversion Price”). If the Company had not exercised the mandatory conversion, the holder of the debt had the option after six months and on up to four occasions to convert all or any portion of the principal and interest into shares of the Company’s common stock at the Conversion Price
CY2023Q4	us-gaap	Convertible Debt ConvertibleDebt	1390000	usd
CY2023Q4	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	1207000	usd
CY2023Q4	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	820160	shares
	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	extended in a series of amendments through March 31, 2025
CY2024Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	20000	usd
CY2023Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	20000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	60000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	60000	usd
CY2022	us-gaap	Multiemployer Plan Increase In Employer Contribution Business Combination Percentage MultiemployerPlanIncreaseInEmployerContributionBusinessCombinationPercentage	0.52	pure
CY2021	us-gaap	Multiemployer Plan Increase In Employer Contribution Business Combination Percentage MultiemployerPlanIncreaseInEmployerContributionBusinessCombinationPercentage	0.42	pure
CY2024Q3	BRFH	Receivables Financing Facility ReceivablesFinancingFacility	1500000	usd
CY2024Q3	us-gaap	Line Of Credit Facility Description LineOfCreditFacilityDescription	Amounts outstanding bear interest at a rate prime plus 1.2% (9.20% as of September 30, 2024) and collateral fees of 0.15% and are secured by accounts receivable and inventory. The Facility terminates on September 5, 2025, and renews automatically, unless notice is given or received. As of September 30, 2024, borrowings under the Facility amounted to $86,000, net of unamortized deferred financing cost of $14,000, and $1,400,000 was available to borrow.
CY2024Q3	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	86000	usd
CY2024Q3	us-gaap	Deferred Costs DeferredCosts	14000	usd
CY2024Q3	us-gaap	Line Of Credit LineOfCredit	1400000	usd
CY2024Q3	BRFH	Debt Instrument Interest Rate Imputed Percentage DebtInstrumentInterestRateImputedPercentage	0.15	pure
CY2024Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.19	pure
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	32000	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	129000	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	136000	usd
CY2024Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	297000	usd
CY2024Q3	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	51000	usd
CY2024Q3	us-gaap	Long Term Debt LongTermDebt	246000	usd
CY2024Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	95000	usd
CY2024Q1	us-gaap	Convertible Debt ConvertibleDebt	2000000	usd
	us-gaap	Debt Instrument Description DebtInstrumentDescription	The debt was available to be drawn in 25% increments, maturing on the anniversary of the draw, bearing interest at 10% per annum for the term, regardless of earlier payment or conversion, and was mandatorily convertible as to principal and interest into shares of the Company’s common stock at any time prior to maturity at the greater of $1.20 or 85% of the volume-weighted average price of the common stock for the ten trading days immediately preceding the written notice of the conversion (the “Conversion Price”). If the Company had not exercised the mandatory conversion, the holder of the debt had the option after six months and on up to four occasions to convert all or any portion of the principal and interest into shares of the Company’s common stock at the Conversion Price
CY2023Q4	us-gaap	Convertible Debt ConvertibleDebt	1390000	usd
CY2023Q4	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	1207000	usd
CY2023Q4	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	820160	shares
CY2023Q4	us-gaap	Convertible Debt ConvertibleDebt	470000	usd
CY2023Q4	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	653000	usd
CY2023Q4	us-gaap	Debt Instrument Periodic Payment Interest DebtInstrumentPeriodicPaymentInterest	4000	usd
CY2023Q4	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	495331	shares
CY2024Q1	us-gaap	Convertible Debt ConvertibleDebt	136000	usd
CY2024Q1	us-gaap	Convertible Debt ConvertibleDebt	136000	usd
CY2024Q3	BRFH	Debt Instrument Interest Rate Imputed Percentage DebtInstrumentInterestRateImputedPercentage	0.15	pure
CY2024Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.19	pure
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	32000	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	129000	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	136000	usd
CY2024Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	297000	usd
CY2024Q3	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	51000	usd
CY2024Q3	us-gaap	Long Term Debt LongTermDebt	246000	usd
CY2024Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	95000	usd
	us-gaap	Debt Instrument Description DebtInstrumentDescription	The debt was available to be drawn in 25% increments, maturing on the anniversary of the draw, bearing interest at 10% per annum for the term, regardless of earlier payment or conversion, and was mandatorily convertible as to principal and interest into shares of the Company’s common stock at any time prior to maturity at the greater of $1.20 or 85% of the volume-weighted average price of the common stock for the ten trading days immediately preceding the written notice of the conversion (the “Conversion Price”). If the Company had not exercised the mandatory conversion, the holder of the debt had the option after six months and on up to four occasions to convert all or any portion of the principal and interest into shares of the Company’s common stock at the Conversion Price
CY2023Q4	us-gaap	Convertible Debt ConvertibleDebt	1390000	usd
CY2023Q4	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	1207000	usd
CY2023Q4	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	820160	shares
CY2023Q4	us-gaap	Convertible Debt ConvertibleDebt	470000	usd
CY2023Q4	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	653000	usd
CY2023Q4	us-gaap	Debt Instrument Periodic Payment Interest DebtInstrumentPeriodicPaymentInterest	4000	usd
CY2023Q4	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	495331	shares
CY2024Q1	us-gaap	Convertible Debt ConvertibleDebt	136000	usd
CY2024Q1	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	124208	shares
CY2023Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	30000	usd
CY2024Q3	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	71000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	2933000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-18000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	514000	usd
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	24000	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	11000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	1293000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	2503000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-20000	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	136000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	1403000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	122739	shares
CY2024Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	9.10
CY2024Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	545000	usd
CY2024Q3	us-gaap	Long Term Debt LongTermDebt	246000	usd
CY2024Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	95000	usd
CY2024Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	151000	usd
CY2024Q1	us-gaap	Convertible Debt ConvertibleDebt	2000000	usd
	us-gaap	Debt Instrument Description DebtInstrumentDescription	The debt was available to be drawn in 25% increments, maturing on the anniversary of the draw, bearing interest at 10% per annum for the term, regardless of earlier payment or conversion, and was mandatorily convertible as to principal and interest into shares of the Company’s common stock at any time prior to maturity at the greater of $1.20 or 85% of the volume-weighted average price of the common stock for the ten trading days immediately preceding the written notice of the conversion (the “Conversion Price”). If the Company had not exercised the mandatory conversion, the holder of the debt had the option after six months and on up to four occasions to convert all or any portion of the principal and interest into shares of the Company’s common stock at the Conversion Price
CY2023Q4	us-gaap	Convertible Debt ConvertibleDebt	1390000	usd
CY2023Q4	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	1207000	usd
CY2023Q4	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	820160	shares
CY2023Q4	us-gaap	Convertible Debt ConvertibleDebt	470000	usd
CY2023Q4	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	653000	usd
CY2023Q4	us-gaap	Debt Instrument Periodic Payment Interest DebtInstrumentPeriodicPaymentInterest	4000	usd
CY2023Q4	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	495331	shares
CY2024Q1	us-gaap	Convertible Debt ConvertibleDebt	136000	usd
CY2024Q1	us-gaap	Convertible Debt ConvertibleDebt	136000	usd
CY2024Q1	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	124208	shares
CY2024Q3	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	71000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	2933000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-18000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	514000	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	11000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	1293000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	2503000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-20000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	757000	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	136000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1973000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	1403000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	122739	shares
CY2024Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	9.10
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.50
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y7M6D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	238482	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.05
	BRFH	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 Issued SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Issued	P8Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	71930	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	7.95
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	753643	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.95
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y3M18D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	540681	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	5.98
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y9M18D
CY2023Q4	us-gaap	Debt Instrument Periodic Payment Interest DebtInstrumentPeriodicPaymentInterest	4000	usd
CY2023Q4	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	495331	shares
CY2024Q1	us-gaap	Convertible Debt ConvertibleDebt	136000	usd
CY2024Q1	us-gaap	Convertible Debt ConvertibleDebt	136000	usd
CY2024Q3	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	71000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	2933000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-18000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	514000	usd
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	24000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2123000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	1293000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	2503000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-20000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	757000	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	136000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1973000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	1403000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	122739	shares
CY2024Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	9.10
CY2024Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	545000	usd
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y7M6D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	238482	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.05
	BRFH	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 Issued SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Issued	P8Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	71930	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	7.95
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	753643	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.95
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y3M18D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	540681	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	5.98
CY2024Q1	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	124208	shares
CY2023Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	30000	usd
CY2024Q3	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	71000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	2933000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-18000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	514000	usd
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	24000	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	11000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2123000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	1293000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	2503000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	2503000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-20000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	757000	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	136000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1973000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	1403000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	1403000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	122739	shares
CY2024Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	9.10
CY2024Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	545000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	587091	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.50
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y7M6D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	238482	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.05
	BRFH	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 Issued SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Issued	P8Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	71930	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	7.95
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	753643	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.95
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	5.98
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y9M18D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	587091	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.50
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y7M6D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	238482	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.05
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	71930	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	7.95
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.95
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y9M18D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P8Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.935	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.042	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	1.77
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P8Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.935	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.042	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	1.77
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2024Q3	BRFH	Working Capital WorkingCapital	1371000	usd
CY2024Q3	us-gaap	Cash Cash	401000	usd
CY2024Q3	us-gaap	Accounts Payable Underwriters Promoters And Employees Other Than Salaries And Wages Current AccountsPayableUnderwritersPromotersAndEmployeesOtherThanSalariesAndWagesCurrent	499000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	320000	usd
CY2024Q3	BRFH	Revenue Percentage1 RevenuePercentage1	0.40	pure
CY2024Q3	BRFH	Receivables Financing Facility ReceivablesFinancingFacility	504000	usd
CY2024Q3	us-gaap	Line Of Credit LineOfCredit	1500000	usd
CY2024Q3	us-gaap	Line Of Credit LineOfCredit	1400000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P8Y
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1544000	usd
CY2024Q3	BRFH	Working Capital WorkingCapital	1371000	usd
CY2024Q3	us-gaap	Cash Cash	401000	usd
CY2024Q3	us-gaap	Accounts Payable Underwriters Promoters And Employees Other Than Salaries And Wages Current AccountsPayableUnderwritersPromotersAndEmployeesOtherThanSalariesAndWagesCurrent	499000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	320000	usd
CY2024Q3	BRFH	Revenue Percentage1 RevenuePercentage1	0.40	pure
CY2024Q3	BRFH	Receivables Financing Facility ReceivablesFinancingFacility	504000	usd
CY2024Q3	us-gaap	Line Of Credit LineOfCredit	1500000	usd
CY2024Q3	us-gaap	Line Of Credit LineOfCredit	1400000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P8Y
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2024Q3	BRFH	Working Capital WorkingCapital	1371000	usd
CY2024Q3	us-gaap	Cash Cash	401000	usd
CY2024Q3	us-gaap	Accounts Payable Underwriters Promoters And Employees Other Than Salaries And Wages Current AccountsPayableUnderwritersPromotersAndEmployeesOtherThanSalariesAndWagesCurrent	499000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	320000	usd
CY2024Q3	BRFH	Revenue Percentage1 RevenuePercentage1	0.40	pure
CY2024Q3	BRFH	Receivables Financing Facility ReceivablesFinancingFacility	504000	usd
CY2024Q3	us-gaap	Line Of Credit LineOfCredit	1500000	usd
CY2024Q3	us-gaap	Line Of Credit LineOfCredit	1400000	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1544000	usd
CY2024Q3	BRFH	Working Capital WorkingCapital	1371000	usd
CY2024Q3	us-gaap	Cash Cash	401000	usd
CY2024Q3	us-gaap	Accounts Payable Underwriters Promoters And Employees Other Than Salaries And Wages Current AccountsPayableUnderwritersPromotersAndEmployeesOtherThanSalariesAndWagesCurrent	499000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	320000	usd
CY2024Q3	BRFH	Revenue Percentage1 RevenuePercentage1	0.40	pure
CY2024Q3	us-gaap	Line Of Credit LineOfCredit	1500000	usd
CY2024Q3	us-gaap	Line Of Credit LineOfCredit	1400000	usd

Files In Submission

Name	View Source	Status
0001493152-24-042368-index-headers.html	Edgar Link	pending
0001493152-24-042368-index.html	Edgar Link	pending
0001493152-24-042368.txt	Edgar Link	pending
0001493152-24-042368-xbrl.zip	Edgar Link	pending
brfh-20240930.xsd	Edgar Link	pending
brfh-20240930_def.xml	Edgar Link	unprocessable
brfh-20240930_lab.xml	Edgar Link	unprocessable
brfh-20240930_pre.xml	Edgar Link	unprocessable
0001493152-24-042368-index-headers.html	Edgar Link	pending
0001493152-24-042368-index.html	Edgar Link	pending
0001493152-24-042368.txt	Edgar Link	pending
0001493152-24-042368-xbrl.zip	Edgar Link	pending
brfh-20240930.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
brfh-20240930_lab.xml	Edgar Link	unprocessable
brfh-20240930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
brfh-20240930_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
brfh-20240930_cal.xml	Edgar Link	unprocessable
brfh-20240930_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BRFH
BARFRESH FOOD GROUP INC. Stock $brfh

2024 Q4 Form 10-Q Financial Statement

#000149315224042368 Filed on October 24, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BRFH BARFRESH FOOD GROUP INC. Stock $brfh

2024 Q4 Form 10-Q Financial Statement

#000149315224042368 Filed on October 24, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BRFH
BARFRESH FOOD GROUP INC. Stock $brfh